SCF^β-TRCP E3 ubiquitin ligase targets the tumor suppressor ZNRF3 for ubiquitination and degradation

Abstract

Wnt signaling has emerged as a major regulator of tissue development by governing the self-renewal and maintenance of stem cells in most tissue types. As a key upstream regulator of the Wnt pathway, the transmembrane E3 ligase ZNRF3 has recently been established to play a role in negative regulation of Wnt signaling by targeting Frizzled (FZD) receptor for ubiquitination and degradation. However, the upstream regulation of ZNRF3, in particular the turnover of ZNRF3, is still unclear. Here we report that ZNRF3 is accumulated in the presence of proteasome inhibitor treatment independent of its E3-ubiquitin ligase activity. Furthermore, the Cullin 1-specific SCF complex containing β-TRCP has been identified to directly interact with and ubiquitinate ZNRF3 thereby regulating its protein stability. Similar with the degradation of β-catenin by β-TRCP, ZNRF3 is ubiquitinated by β-TRCP in both CKI-phosphorylation-and degron-dependent manners. Thus, our findings not only identify a novel substrate for β-TRCP oncogenic regulation, but also highlight the dual regulation of Wnt signaling by β-TRCP in a contextdependent manner where β-TRCP negatively regulates Wnt signaling by targeting β-catenin, and positively regulates Wnt signaling by targeting ZNRF3.

Keywords

ZNRF3 / β-TRCP / Wnt / ubiquitination / CKI

References

[1] Akhoondi S (2007) FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res 67:9006–9012

[2] Behrens J (1998) Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3beta. Science 280:596–599

[3] Busino L (2003) Degradation of Cdc25A by beta-TrCP during S phase and in response to DNA damage. Nature 426:87–91

[4] Clevers H (2006) Wnt/beta-catenin signaling in development and disease. Cell 127:469–480

[5] de Bie P, Ciechanover A (2011) Ubiquitination of E3 ligases: selfregulation of the ubiquitin system via proteolytic and nonproteolytic mechanisms. Cell Death Differ 18:1393–1402

[6] Espada J, Calvo MB, Diaz-Prado S, Medina V (2009) Wnt signalling and cancer stem cells. Clin Transl Oncol 11:411–427

[7] Fuchs SY, Spiegelman VS, Kumar KG (2004) The many faces of beta-TrCP E3 ubiquitin ligases: reflections in the magic mirror of cancer. Oncogene 23:2028–2036

[8] Gao D (2011) mTOR drives its own activation via SCF (betaTrCP)-dependent degradation of the mTOR inhibitor DEPTOR. Mol Cell 44:290–303

[9] Goldstein B, Takeshita H, Mizumoto K, Sawa H (2006) Wnt signals can function as positional cues in establishing cell polarity. Dev Cell 10:391–396

[10] Guardavaccaro D (2003) Control of meiotic and mitotic progression by the F box protein beta-Trcp1 in vivo. Dev Cell 4:799–812

[11] Guo J (2016) pVHL suppresses kinase activity of Akt in a proline-hydroxylation-dependent manner. Science 353:929–932

[12] Hao HX (2012) ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner. Nature 485:195–200

[13] Hart M (1999) The F-box protein beta-TrCP associates with phosphorylated beta-catenin and regulates its activity in the cell. Curr Biol 9:207–210

[14] Kimelman D, Xu W (2006) beta-catenin destruction complex: insights and questions from a structural perspective. Oncogene 25:7482–7491

[15] Koo BK (2012) Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors. Nature 488:665–669

[16] Kudo Y (2004) Role of F-box protein betaTrcp1 in mammary gland development and tumorigenesis. Mol Cell Biol 24:8184–8194

[17] Lammi L (2004) Mutations in AXIN2 cause familial tooth agenesis and predispose to colorectal cancer. Am J Hum Genet 74:1043–1050

[18] Lustig B (2002) Negative feedback loop of Wnt signaling through upregulation of conductin/axin2 in colorectal and liver tumors. Mol Cell Biol 22:1184–1193

[19] MacDonald BT, He X (2012) Frizzled and LRP5/6 receptors for Wnt/beta-catenin signaling. Cold Spring Harb Perspect Biol 4:12

[20] Morin PJ (1997) Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 275:1787–1790

[21] Nakayama K (2003) Impaired degradation of inhibitory subunit of NF-kappa B (I kappa B) and beta-catenin as a result of targeted disruption of the beta-TrCP1 gene. Proc Natl Acad Sci USA 100:8752–8757

[22] Nusse R, Clevers H (2017) Wnt/beta-catenin signaling, disease, and emerging therapeutic modalities. Cell 169:985–999

[23] Nusse R, Varmus HE (1982) Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell 31:99–109

[24] Peifer M, Polakis P (2000) Wnt signaling in oncogenesis and embryogenesis—a look outside the nucleus. Science 287:1606–1609

[25] Rubinfeld B (1993) Association of the APC gene product with beta-catenin. Science 262:1731–1734

[26] Rubinfeld B (1996) Binding of GSK3beta to the APC-betacatenin complex and regulation of complex assembly. Science 272:1023–1026

[27] Saitoh T, Katoh M (2001) Expression profiles of betaTRCP1 and betaTRCP2, and mutation analysis of betaTRCP2 in gastric cancer. Int J Oncol 18:959–964

[28] Sarikas A, Hartmann T, Pan ZQ (2011) The cullin protein family. Genome Biol 12:220

[29] Scaglione KM (2007) SCF E3-mediated autoubiquitination negatively regulates activity of Cdc34 E2 but plays a nonessential role in the catalytic cycle in vitro and in vivo. Mol Cell Biol 27:5860–5870

[30] Shen M, Schmitt S, Buac D, Dou QP (2013) Targeting the ubiquitinproteasome system for cancer therapy. Expert Opin Ther Targets 17:1091–1108

[31] Shimizu K (2017) The SCFbeta-TRCP E3 ubiquitin ligase complex targets Lipin1 for ubiquitination and degradation to promote hepatic lipogenesis. Sci Signal. https://doi.org/10.1126/scisignal.aah4117

[32] Skowyra D, Craig KL, Tyers M, Elledge SJ, Harper JW (1997) F-box proteins are receptors that recruit phosphorylated substrates to the SCF ubiquitin-ligase complex. Cell 91:209–219

[33] Soucy TA (2009) An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 458:732–736

[34] Sparks AB, Morin PJ, Vogelstein B, Kinzler KW (1998) Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res 58:1130–1134

[35] Spencer E, Jiang J, Chen ZJ (1999) Signal-induced ubiquitination of IkappaBalpha by the F-box protein Slimb/beta-TrCP. Genes Dev 13:284–294

[36] Spranger S, Bao R, Gajewski TF (2015) Melanoma-intrinsic betacatenin signalling prevents anti-tumour immunity. Nature 523:231–235

[37] Toomes C (2004) Spectrum and frequency of FZD4 mutations in familial exudative vitreoretinopathy. Invest Ophthalmol Vis Sci 45:2083–2090

[38] Van Wesenbeeck L (2003) Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am J Hum Genet 72:763–771

[39] Wang Z, Liu P, Inuzuka H, Wei W (2014) Roles of F-box proteins in cancer. Nat Rev Cancer 14:233–247

[40] Wang Z (2015) SCF(beta-TRCP) promotes cell growth by targeting PR-Set7/Set8 for degradation. Nat Commun 6:10185

[41] Welcker M, Clurman BE (2008) FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer 8:83–93

[42] Westbrook TF (2008) SCFbeta-TRCP controls oncogenic transformation and neural differentiation through REST degradation. Nature 452:370–374

[43] Yang K (2017) Homeostatic control of metabolic and functional fitness of Treg cells by LKB1 signalling. Nature 548:602–606

RIGHTS & PERMISSIONS

2018 The Author(s) 2018. This article is an open access publication